KNSA Insider Trading

Insider Ownership Percentage: 54.57%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $9,380,104.31

Kiniksa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Kiniksa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.54MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Kiniksa Pharmaceuticals Share Price & Price History

Current Price: $22.61
Price Change: Price Increase of +0.45 (2.03%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for KNSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$22.61Closing price on 03/14/25:

SEC Filings (Institutional Ownership Changes) for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

53.95% of Kiniksa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KNSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$56Mbought$59MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Kiniksa Pharmaceuticals logo
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More on Kiniksa Pharmaceuticals

Today's Range

Now: $22.61
Low: $22.02
High: $22.86

50 Day Range

MA: $19.95
Low: $18.17
High: $22.50

52 Week Range

Now: $22.61
Low: $16.56
High: $28.15

Volume

595,003 shs

Average Volume

407,191 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Who are the company insiders with the largest holdings of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' top insider shareholders include:
  1. Eben Tessari (COO)
  2. Sanj K Patel (CEO)
  3. John F Paolini (Insider)
  4. Michael R Megna (CAO)
  5. Mark Ragosa (CFO)
Learn More about top insider investors at Kiniksa Pharmaceuticals.

Who are the major institutional investors of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' top institutional shareholders include:
  1. Braidwell LP — 4.78%
  2. Vanguard Group Inc. — 4.44%
  3. Fairmount Funds Management LLC — 3.04%
  4. Pictet Asset Management Holding SA — 1.57%
  5. Nuveen Asset Management LLC — 1.10%
  6. Millennium Management LLC — 1.08%
Learn More about top institutional investors of Kiniksa Pharmaceuticals stock.

Which major investors are selling Kiniksa Pharmaceuticals stock?

During the last quarter, KNSA stock was sold by these institutional investors:
  1. Fairmount Funds Management LLC
  2. ADAR1 Capital Management LLC
  3. Jane Street Group LLC
  4. Arrowstreet Capital Limited Partnership
  5. Ameriprise Financial Inc.
  6. Driehaus Capital Management LLC
  7. Vanguard Group Inc.
  8. Trexquant Investment LP
During the previous year, company insiders that have sold Kiniksa Pharmaceuticals company stock include:
  1. Eben Tessari (COO)
  2. Sanj K Patel (CEO)
  3. John F Paolini (Insider)
  4. Michael R Megna (CAO)
  5. Mark Ragosa (CFO)
Learn More investors selling Kiniksa Pharmaceuticals stock.

Which major investors are buying Kiniksa Pharmaceuticals stock?

In the previous quarter, KNSA stock was bought by institutional investors including:
  1. Braidwell LP
  2. JPMorgan Chase & Co.
  3. Millennium Management LLC
  4. Raymond James Financial Inc.
  5. Raymond James Financial Inc.
  6. Hudson Bay Capital Management LP
  7. ExodusPoint Capital Management LP
  8. Deutsche Bank AG